Chronic Lymphocytic Leukemia

Nakhle Saba, MD, reviewed testing, treatment, and treatment toxicity in a 71-year-old woman with chronic lymphocytic leukemia with a group of peers during a Targeted Oncology case-based roundtable event.

Dosing of NX-2127 in patients with chronic lymphocytic leukemia has begun in a phase 1b clinical trial.

Catherine Coombs, MD, MS, shares her thoughts on the future of treatment and where the field is moving for patients with CLL.

A detailed description of emerging treatment options for patients with relapsed/refractory CLL.

Catherine Coombs, MD, MS, highlights available data and considerations for retreatment with venetoclax in the relapsed/refractory setting.

A comprehensive review of existing second-line treatment options for patients with R/R CLL.

Catherine Coombs, MD, MS, reviews factors that impact the selection of treatment in patients with CLL.

An expert in treating CLL discusses potential treatment options for a patient with relapsed/refractory CLL who has been previously treated with venetoclax plus obinutuzumab.

Catherine Coombs, MD, MS, introduces the case of a patient with relapsed/refractory CLL and shares her impressions on the patient’s initial presentation.

In season 3, episode 4 of Targeted Talks, Alexey Danilov, MD, PhD, discusses the shift toward utilizing cellular therapy to treat high-risk patients with chronic lymphocytic leukemia.

Targeted agents, such as Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and venetoclax, have delivered improvements in quality of life, progression-free survival, and overall survival for relapsed/refractory chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses the results of the phase 3 ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.

In an interview with Targeted Oncology, Wojciech Jurczak, MD, PhD, discussed the clinical trial investigation of ceralasertib with or without acalabrutinib in patients with high-risk relapsed or refractory chronic lymphocytic leukemia.

Mazyar Shadman, MD, MPH, discusses the use of MB-106 for the treatment of patients with relapsed or refractory B-cell nonHodgkin lymphoma and chronic lymphocytic leukemia.

During a Targeted Oncology case-based event, Lindsey Roeker, MD, discussed risk assessment and frontline therapy for a patient diagnosed with chronic lymphocytic leukemia.

John F. Seymour, MBBS, PhD, discusses the rationale for a post-hoc analysis of the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

John Allan, MD, speaks to the exciting future of treatments for chronic lymphocytic leukemia.

Dr John Allan discusses the adverse events he monitors for with select treatments for chronic lymphocytic leukemia, and when he decides to move to second-line therapy.

An expert in hematologic malignancies describes how he would monitor a patient on frontline treatment with newly diagnosed chronic lymphocytic leukemia.

John Allan, MD, explains how fitness level and comorbidities affect his treatment selections for chronic lymphocytic leukemia and whether he prefers fixed-duration or continuous-strategy approaches.

Dr John Allan gives an overview of the frontline treatment options available for chronic lymphocytic leukemia with reference to clinical trial data.

A leukemia expert discusses ongoing challenges in chronic lymphocytic leukemia treatment, and how to discuss risk stratification with a patient.

John Allan, MD, presents the case of a 70-year-old woman with newly diagnosed chronic lymphocytic leukemia.

With an increasing imbalance in overall survival, the FDA approval application for the combination of ublituximab and umbralisib for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdrawn.

The past decade has seen the FDA approve a handful of new targeted therapies for chronic lymphocytic leukemia that are prompting a move toward chemotherapy-free treatment of the disease.